Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for allegedly failing to disclose critical information regarding its business prospects, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [2]. - On June 23, 2025, BMO downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, resulting in a 3.21% drop in stock price to $26.87 [3]. - Dow reported disappointing Q2 2025 results on July 24, 2025, with a non-GAAP loss per share of $0.42, significantly worse than the expected loss of $0.17 to $0.18, and net sales of $10.1 billion, a 7.3% year-over-year decline, missing estimates by $130 million. The company also announced a 50% cut in its dividend, causing a 17.45% drop in stock price to $25.07 [4]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Dow Inc. and can contact Robbins LLP if they wish to serve as lead plaintiff, representing other class members [5]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [5].

Core Viewpoint - A class action lawsuit has been filed against Dow Inc. for allegedly failing to disclose critical information regarding its business prospects, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Financial Performance - The lawsuit claims that Dow overstated its ability to handle macroeconomic challenges and maintain financial flexibility for dividends, while understating the negative impacts of competitive pressures, declining global sales, and product oversupply [2]. - On June 23, 2025, BMO downgraded Dow's stock from "Market Perform" to "Underperform," reducing the price target from $29.00 to $22.00, resulting in a 3.21% drop in stock price to $26.87 [3]. - Dow reported disappointing Q2 2025 results on July 24, 2025, with a non-GAAP loss per share of $0.42, exceeding analyst expectations of a loss between $0.17 and $0.18. Net sales were $10.1 billion, a 7.3% year-over-year decline, missing estimates by $130 million. Additionally, Dow announced a 50% cut in its dividend, causing a 17.45% drop in stock price to $25.07 [4]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action against Dow Inc. and can contact Robbins LLP if they wish to serve as lead plaintiff [5]. - The lead plaintiff represents other class members in directing the litigation, and shareholders can remain absent class members if they choose not to participate [5]. Group 3: Company Background - Dow Inc. is an American materials science company that serves various industries, including packaging, infrastructure, mobility, and consumer applications [1].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) for alleged deficiencies in its internal control over financial reporting, leading to improper revenue recognition and the need for restatement of financial statements [1][2]. Allegations - The complaint states that Quantum Corporation failed to disclose improper revenue recognition during the fiscal year ended March 31, 2025 [2]. - As a result of these deficiencies, Quantum Corporation will need to restate its financial statements for the fiscal third quarter ended December 31, 2024 [2]. - The statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [2]. Financial Impact - On August 8, 2025, Quantum Corporation announced that its 3Q24 financials would be restated, reflecting a decrease of approximately $3.9 million in revenue [3]. - The company also disclosed material weaknesses in its internal control over financial reporting and disclosure controls as of December 31, 2024, and March 31, 2025 [3]. Management Changes - Following the financial disclosures, Quantum Corporation's CFO announced resignation on August 18, 2025, after holding the position for less than five months [3].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during the specified class period [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2][3]. Group 2: Financial Impact and Stock Performance - Following disappointing results announced on August 6, 2025, Lantheus reported an 8.3% year-over-year decline in Pylarify's performance and significantly reduced its growth projections for fiscal year 2025 [4]. - The announcement led to a sharp decline in Lantheus' stock price, dropping from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, representing a decline of approximately 28.8% in one day [4].

Core Viewpoint - Rosen Law Firm is urging investors of Capricor Therapeutics, Inc. to contact them regarding a class action lawsuit due to alleged misleading information about the company's business operations and its lead drug candidate, deramiocel [1][2][3]. Summary by Sections Allegations - The lawsuit claims that Capricor provided investors with misleading information about deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [3]. - Defendants allegedly made positive statements about obtaining a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the safety and efficacy data from the Phase 2 HOPE-2 trial [3]. Class Action Participation - Shareholders wishing to serve as lead plaintiffs must file motions by September 15, 2025, and can remain absent class members if they choose not to participate [4]. - The law firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. About Rosen Law Firm - Rosen Law Firm is recognized for its leadership in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) due to allegations of deficiencies in its internal control over financial reporting, leading to improper revenue recognition and the need to restate financial statements [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Quantum Corporation improperly recognized revenue during the fiscal year ended March 31, 2025, necessitating a restatement of previously filed financial statements for the fiscal third quarter ended December 31, 2024 [2]. - On August 8, 2025, Quantum Corporation announced that its 3Q24 financials could not be relied upon and would be restated, indicating a decrease of approximately $3.9 million in revenue [3]. - The company disclosed material weaknesses in its internal control over financial reporting and disclosure controls as of December 31, 2024, and March 31, 2025 [3]. Group 2: Management Changes - Following the financial disclosures, Quantum Corporation announced the resignation of its CFO on August 18, 2025, after holding the position for less than five months [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Quantum Corporation, with options to serve as lead plaintiff or remain an absent class member [4].

SAN DIEGO, Sept. 4, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Quantum Corporation (NASDAQ: QMCO) securities between November 15, 2024 and August 18, 2025. Quantum Corporation is a technology company focused on data management solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations ...

Core Viewpoint - A class action lawsuit has been filed against Tronox Holdings PLC for allegedly failing to disclose accurate business prospects and misleading investors regarding its revenue outlook and growth potential [1][2]. Group 1: Allegations and Financial Impact - The complaint claims that Tronox misrepresented its ability to forecast demand for its titanium dioxide (TiO2) and zircon products, leading to an unrealistic portrayal of its margin growth goals [2]. - On July 30, 2025, Tronox reported a significant decline in TiO2 sales, attributing it to a weaker coatings season and increased competition, which led to a revision of its 2025 financial outlook and a 60% reduction in dividends [3]. - Following the announcement, Tronox's stock price plummeted from $5.14 to $3.19 per share, marking a decline of approximately 38% [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action must file their papers by November 3, 2025, to serve as lead plaintiff, representing other class members in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without taking any action [4]. Group 3: Company Background - Robbins LLP, the firm leading the class action, specializes in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [5].

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, and/or traceable to the Company's May 21, 2025 secondary public offering [1] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not [2] - The complaint indicates that investors suffered damage when the true details regarding oil production were revealed [2] Group 2 - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025 [3] - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]

Core Points - A class action has been filed against C3.ai, Inc. on behalf of investors who acquired its securities between February 26, 2025, and August 8, 2025 [1] - Allegations include misleading investors about the impact of the CEO's health on the company's business prospects and its ability to close deals [2] - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year, attributing this to CEO health issues and management reorganization [3] Legal Proceedings - Shareholders wishing to serve as lead plaintiffs must submit their papers by October 21, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5]